Disease on EC 1.17.4.2 - ribonucleoside-triphosphate reductase (thioredoxin)
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Acquired Immunodeficiency Syndrome
Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment.
Adenocarcinoma
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Adenocarcinoma
Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells.
Adenocarcinoma
Early loss of the tyrosyl radical in ribonucleotide reductase of adenocarcinoma cells producing nitric oxide.
Adenocarcinoma
Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.
Adenocarcinoma
Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy.
Adenocarcinoma
Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells.
Adenocarcinoma
Inhibition of ribonucleotide reductase by nitric oxide derived from thionitrites: reversible modifications of both subunits.
Adenocarcinoma
Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.
Adenocarcinoma
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.
Adenocarcinoma
Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
Adenocarcinoma
Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
Adenocarcinoma
Ribonucleotide reductase immunoreactivity in adenocarcinoma cells and malignant or reactive mesothelial cells in serous effusions.
Adenocarcinoma
Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Adenocarcinoma
Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003.
Adenocarcinoma
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Adenocarcinoma
Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
Adenocarcinoma of Lung
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
adenosine deaminase deficiency
Adenosine deaminase impairment and ribonucleotide reductase activity and levels in HeLa cells.
adenosine deaminase deficiency
Characterization of a cultured human T-cell line with genetically altered ribonucleotide reductase activity. Model for immunodeficiency.
adenosine deaminase deficiency
Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency.
adenosine deaminase deficiency
Effects of deoxyadenosine on ribonucleotide reductase in adenosine deaminase-deficient lymphocytes.
Adrenal Cortex Neoplasms
Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.
Adrenocortical Carcinoma
Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment.
African Swine Fever
Gel retardation analysis of ribonucleotide reductase gene expression in African swine fever virus.
African Swine Fever
Induction of ribonucleotide reductase activity in cells infected with African swine fever virus.
African Swine Fever
The sequences of the ribonucleotide reductase genes from African swine fever virus show considerable homology with those of the orthopoxvirus, vaccinia virus.
Anemia
The effects of lithium in reversing hydroxyurea induced suppression of hematopoietic progenitor cells in vitro using retroviral infected long-term marrow cultures.
Anemia
Trimidox-mediated morphological changes during erythroid differentiation is associated with the stimulation of hemoglobin and F-cell production in human K562 cells.
Anemia, Pernicious
Leukocyte ribonucleotide reductase: studies in normal subjects and in subjects with leukemia or pernicious anemia.
Anemia, Sickle Cell
Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin.
Anemia, Sickle Cell
Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation.
Anemia, Sickle Cell
The effects of lithium in reversing hydroxyurea induced suppression of hematopoietic progenitor cells in vitro using retroviral infected long-term marrow cultures.
Anemia, Sickle Cell
The in vivo toxicity of hydroxyurea depends on its direct target catalase.
Anemia, Sickle Cell
Trimidox-mediated morphological changes during erythroid differentiation is associated with the stimulation of hemoglobin and F-cell production in human K562 cells.
Arthritis, Infectious
Ribonucleotide reductase class III, an essential enzyme for the anaerobic growth of Staphylococcus aureus, is a virulence determinant in septic arthritis.
Ataxia
A series of N-carbamoyloxyurea resistant cell lines with alterations in ribonucleotide reductase: lack of coordination in pyrimidine and purine reductase activity.
Ataxia Telangiectasia
Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis.
Ataxia Telangiectasia
ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.
Ataxia Telangiectasia
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Ataxia Telangiectasia
Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Atherosclerosis
Ribonucleotide reductase inhibitors reduce atherosclerosis in a double-injury rabbit model.
Biliary Tract Neoplasms
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Brain Neoplasms
Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase.
Brain Neoplasms
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Brain Neoplasms
Experimental combination chemotherapy with thymidylate synthetase and ribonucleotide reductase inhibitors.
Brain Neoplasms
The cytotoxicity of gallium maltolate in glioblastoma cells is enhanced by metformin through combined action on mitochondrial complex 1.
Brain Neoplasms
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.
Breast Neoplasms
Acquired tamoxifen resistance is surmounted by GW8510 through ribonucleotide reductase M2 downregulation-mediated autophagy induction.
Breast Neoplasms
An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.
Breast Neoplasms
Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.
Breast Neoplasms
Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?
Breast Neoplasms
Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells.
Breast Neoplasms
Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma.
Breast Neoplasms
Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma.
Breast Neoplasms
ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Breast Neoplasms
Establishment of human pancreatic cancer gemcitabine?resistant cell line with ribonucleotide reductase overexpression.
Breast Neoplasms
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Breast Neoplasms
Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, ?-tubulin III, thymidylate synthetase, and topoisomerase II? in breast cancer: Association with clinicopathological characteristics.
Breast Neoplasms
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.
Breast Neoplasms
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Breast Neoplasms
How close are we to customizing chemotherapy in early non-small cell lung cancer?
Breast Neoplasms
Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
Breast Neoplasms
Molecular Targeting of RRM2, NF-?B, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer.
Breast Neoplasms
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Breast Neoplasms
Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
Breast Neoplasms
Prediction of a Side Effect and Efficacy of Adjuvant Chemotherapy with Gemcitabine for Post Operative Patient of Pancreatic Cancer by a Genetic Polymorphism Analysis.
Breast Neoplasms
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Breast Neoplasms
Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Breast Neoplasms
Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products.
Breast Neoplasms
Reactions of purines-containing butenolides with L-cysteine or N-acetyl-L-cysteine as model biological nucleophiles: a potent mechanism-based inhibitor of ribonucleotide reductase caused apoptosis in breast carcinoma MCF7 cells.
Breast Neoplasms
Ribonucleotide reductase subunit M2B deficiency leads to mitochondrial permeability transition pore opening and is associated with aggressive clinicopathologic manifestations of breast cancer.
Breast Neoplasms
RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum.
Breast Neoplasms
RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.
Breast Neoplasms
Sequence analysis of the large and small subunits of human ribonucleotide reductase.
Breast Neoplasms
Targeting ribonucleotide reductase M2 and NF-?B activation with Didox to circumvent tamoxifen resistance in breast cancer.
Breast Neoplasms
The SNHG16/miR-30a axis promotes breast cancer cell proliferation and invasion by regulating RRM2.
Breast Neoplasms
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
Breast Neoplasms
[Silencing RRM1 gene reverses paclitaxel resistance in human breast cancer cell line MCF- 7/R by inducing cell apoptosis].
Burkitt Lymphoma
Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: synthesis and antiproliferative activity.
Burkitt Lymphoma
Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype.
Carcinogenesis
Bioinformatics analysis revealing prognostic significance of RRM2 gene in breast cancer.
Carcinogenesis
Conditional expression of 15-lipoxygenase-1 inhibits the selenoenzyme thioredoxin reductase: modulation of selenoproteins by lipoxygenase enzymes.
Carcinogenesis
Design, synthesis and cytotoxic evaluation of o-carboxamido stilbene analogues.
Carcinogenesis
Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells.
Carcinogenesis
Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer.
Carcinogenesis
Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?
Carcinogenesis
Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation.
Carcinogenesis
The expression of ribonucleotide reductase m2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.
Carcinoma
Antitumor and radiosensitizing effects of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, a novel inhibitor of ribonucleoside diphosphate reductase, on human colon carcinoma xenografts in nude mice.
Carcinoma
Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector.
Carcinoma
Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Carcinoma
De novo deoxyribonucleotide biosynthesis regulates cell growth and tumor progression in small-cell lung carcinoma.
Carcinoma
Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity.
Carcinoma
Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture.
Carcinoma
Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells.
Carcinoma
Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, ?-tubulin III, thymidylate synthetase, and topoisomerase II? in breast cancer: Association with clinicopathological characteristics.
Carcinoma
Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
Carcinoma
Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy.
Carcinoma
Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase.
Carcinoma
Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives.
Carcinoma
Metabolism and ribonucleotide reductase inhibition of (E)-2'-deoxy-2'-(fluoromethylene)cytidine, MDL 101,731, in human cervical carcinoma HeLa S3 cells.
Carcinoma
Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).
Carcinoma
Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.
Carcinoma
Quantitation of G0 and G1 phase cells in primary carcinomas. Antibody to M1 subunit of ribonucleotide reductase shows G1 phase restriction point block.
Carcinoma
Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma.
Carcinoma
Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
Carcinoma
Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients.
Carcinoma
Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Carcinoma
Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma.
Carcinoma
Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.
Carcinoma
Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status.
Carcinoma
Structural aspects of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of L1210 cell growth and ribonucleotide reductase activity.
Carcinoma
Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytoxicity by hydroxyurea.
Carcinoma
The relationship between the antitumor activity and the ribonucleotide reductase inhibitory activity of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, MDL 101,731.
Carcinoma
The ribonucleotide reductase inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells.
Carcinoma
[Studies on the thymidine-triphosphate synthesis in malignant tumors. I. Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis (author's trans)]
Carcinoma
[Studies on the thymidine-triphosphate synthesis in malignant tumors. II. Effect of hyperthermia, Vitamin K and Cytotoxic agents (author's transl)]
Carcinoma, Ductal
Identification of genes expressed in premalignant breast disease by microscopy-directed cloning.
Carcinoma, Ehrlich Tumor
Properties of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of mammalian ribonucleotide reductase.
Carcinoma, Ehrlich Tumor
Quenching of tyrosine radicals of M2 subunit from ribonucleotide reductase in tumor cells by different antitumor agents: an EPR study.
Carcinoma, Ehrlich Tumor
Ribonucleotide reductase activity during the growth of Ehrlich ascites tumor.
Carcinoma, Ehrlich Tumor
Ribonucleotide reductase and DNA synthesis in Ehrlich ascites tumor cells.
Carcinoma, Ehrlich Tumor
Ribonucleotide reductase in melanoma tissue. EPR detection in human amelanotic melanoma and quenching of the tyrosine radical by 4-hydroxyanisole.
Carcinoma, Hepatocellular
Cytotoxic and cell kinetic effects of 3,4,5-trihydroxybenzohydroxamic acid (VF 122) in hepatoma 3924A cells.
Carcinoma, Hepatocellular
High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.
Carcinoma, Hepatocellular
Pterostilbene inhibits hepatocellular carcinoma proliferation and HBV replication by targeting ribonucleotide reductase M2 protein.
Carcinoma, Hepatocellular
Relationship between pyridine nucleotide levels and ribonucleotide reductase activity in Yoshida ascites hepatoma AH130.
Carcinoma, Hepatocellular
Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas.
Carcinoma, Hepatocellular
Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Ribonucleotide reductase subunit M2 can be new molecular target and prognostic biomarker of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.
Carcinoma, Hepatocellular
Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma.
Carcinoma, Hepatocellular
[Mitochondrial thymidine kinase and ribonucleotide reductase from rat liver and rat hepatoma 27]
Carcinoma, Intraductal, Noninfiltrating
Identification of genes expressed in premalignant breast disease by microscopy-directed cloning.
Carcinoma, Non-Small-Cell Lung
(18)F-fluorodeoxyglucose Uptake with Expression of Excision Repair Cross-complementary Group 1 and Ribonucleotide Reductase Subunit M1 in Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Carcinoma, Non-Small-Cell Lung
Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
Carcinoma, Non-Small-Cell Lung
ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Carcinoma, Non-Small-Cell Lung
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.
Carcinoma, Non-Small-Cell Lung
ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Carcinoma, Non-Small-Cell Lung
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Expression of RRM1 and its correlation with sensitivity to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
Carcinoma, Non-Small-Cell Lung
Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Molecular predictors of response to chemotherapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations.
Carcinoma, Non-Small-Cell Lung
mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy.
Carcinoma, Non-Small-Cell Lung
P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: A meta-analysis.
Carcinoma, Non-Small-Cell Lung
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status.
Carcinoma, Non-Small-Cell Lung
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
Carcinoma, Non-Small-Cell Lung
RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine.
Carcinoma, Non-Small-Cell Lung
Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
Carcinoma, Non-Small-Cell Lung
The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
Carcinoma, Non-Small-Cell Lung
The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival.
Carcinoma, Non-Small-Cell Lung
[Differential expressions of MDR-1, RRM-1, EGFR and ERCC-1 in primary tumors and metastatic lymph nodes of NSCLC patients].
Carcinoma, Non-Small-Cell Lung
[Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and ?-tubulin3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy]
Carcinoma, Non-Small-Cell Lung
[Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines]
Carcinoma, Non-Small-Cell Lung
[Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients].
Carcinoma, Ovarian Epithelial
Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.
Carcinoma, Renal Cell
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
Carcinoma, Renal Cell
Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).
Carcinoma, Renal Cell
Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma.
Carcinoma, Squamous Cell
Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
Carcinoma, Squamous Cell
Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy.
Carcinoma, Squamous Cell
Loss of the tyrosyl radical in mouse ribonucleotide reductase by (-)-epicatechin.
Chickenpox
Ribonucleotide reductase induced by varicella zoster virus. Characterization, and potentiation of acyclovir by its inhibition.
Chickenpox
Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice.
Cholangiocarcinoma
Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
Cholangiocarcinoma
Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma.
Choriocarcinoma
[Effect of antisense oligodeoxynucleotide of small subunit component of human ribonucleotide reductase on human choriocarcinoma cell line in vitro]
Classical Swine Fever
Role of viral proteins and concanavalin A in in vitro replication of pseudorabies virus in porcine peripheral blood mononuclear cells.
Colonic Neoplasms
Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma.
Colonic Neoplasms
E2F4 and ribonucleotide reductase mediate S-phase arrest in colon cancer cells treated with chlorophyllin.
Colonic Neoplasms
Interferon augments the cytotoxicity of hydroxyurea without enhancing its activity against the M2 subunit of ribonucleotide reductase: effects in wild-type and resistant human colon cancer cells.
Colonic Neoplasms
Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity.
Colonic Neoplasms
Reverse transcriptase template switching during reverse transcriptase-polymerase chain reaction: artificial generation of deletions in ribonucleotide reductase mRNA.
Colonic Neoplasms
Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003.
Colonic Neoplasms
Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.
Colonic Neoplasms
Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors.
Colorectal Neoplasms
CREB1 directly activates the transcription of ribonucleotide reductase small subunit M2 and promotes the aggressiveness of human colorectal cancer.
Colorectal Neoplasms
E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
Colorectal Neoplasms
Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.
Colorectal Neoplasms
Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy.
Colorectal Neoplasms
Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer.
Colorectal Neoplasms
Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.
Colorectal Neoplasms
Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.
Colorectal Neoplasms
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
Deficiency Diseases
Adenosine deaminase impairment and ribonucleotide reductase activity and levels in HeLa cells.
Deficiency Diseases
Cockayne's syndrome fibroblasts are characterized by hypersensitivity to deoxyguanosine and abnormal DNA precursor pool metabolism in response to deoxyguanosine or ultraviolet light.
Dehydration
Dehydration of ribonucleotides catalyzed by ribonucleotide reductase: the role of the enzyme.
Demyelinating Diseases
A monoclonal antibody against HSV type 1 ribonucleotide reductase cross-reacts with the P0 protein of peripheral nerve myelin.
Endocarditis
Streptococcus sanguinis class Ib ribonucleotide reductase: high activity with both iron and manganese cofactors and structural insights.
Endometrial Neoplasms
[Effect of cinobufotalin on growth of xenograft of endometrial carcinoma cell line ishikawa in nude mouse and its impact on RRM2 expression].
Escherichia coli Infections
Correction for Dreux et al., Ribonucleotide Reductase Repressor NrdR as a Novel Regulator for Motility and Chemotaxis during Adherent-Invasive Escherichia coli Infection.
Escherichia coli Infections
Ribonucleotide reductase NrdR as a novel regulator for motility and chemotaxis during adherent-invasive Escherichia coli infection.
Fibrosarcoma
Involvement of oxidants and oxidant-generating enzyme(s) in tumour-necrosis-factor-alpha-mediated apoptosis: role for lipoxygenase pathway but not mitochondrial respiratory chain.
Focal Epithelial Hyperplasia
Disturbed expression of ribonucleotide reductase and cytokeratin polypeptides in focal epithelial hyperplasia. An immunohistochemical study using monoclonal antibodies.
Fowlpox
Gene translocations in poxviruses: the fowlpox virus thymidine kinase gene is flanked by 15 bp direct repeats and occupies the locus which in vaccinia virus is occupied by the ribonucleotide reductase large subunit gene.
Gastrointestinal Neoplasms
Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.
Genetic Diseases, Inborn
Hydroxyurea attenuates oxidative, metabolic, and excitotoxic stress in rat hippocampal neurons and improves spatial memory in a mouse model of Alzheimer's disease.
Gestational Trophoblastic Disease
[Expression of R2 protein in gestational trophoblastic diseases.]
Glioblastoma
(E)-2'-deoxy-2'-(fluoromethylene) cytidine potentiates radioresponse of two human solid tumor xenografts.
Glioblastoma
Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase.
Glioblastoma
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Glioblastoma
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Glioblastoma
The cytotoxicity of gallium maltolate in glioblastoma cells is enhanced by metformin through combined action on mitochondrial complex 1.
Glioblastoma
The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate.
Glioblastoma
The role of DNA synthesis inhibition in the cytotoxicity of 2',2'-difluoro-2'-deoxycytidine.
Glioma
MicroRNA-1468-5p inhibits glioma cell proliferation and induces cell cycle arrest by targeting RRM1.
Gliosarcoma
Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
Head and Neck Neoplasms
A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
Heart Failure
Molecular Targeting of RRM2, NF-?B, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer.
Hematologic Neoplasms
Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Hematologic Neoplasms
Effect of clofarabine on apoptosis and DNA synthesis in human epithelial colon cancer cells.
Hematologic Neoplasms
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Hematologic Neoplasms
Ribonucleotide reductase and thymidine kinase activities in various cultured cell lines derived from hematologic malignancies.
Hepatitis B
Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein.
Hepatitis C
Ribonucleotide reductase M2 promotes RNA replication of hepatitis C virus by protecting NS5B protein from hPLIC1-dependent proteasomal degradation.
Hepatoblastoma
The 11p15.5 ribonucleotide reductase M1 subunit locus is not imprinted in Wilms' tumour and hepatoblastoma.
Herpes Genitalis
Therapeutic Mucosal Vaccination of HSV-2 Infected Guinea Pigs with the Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Tissue-Resident CD4+ and CD8+ TRM Cells Associated with Protection Against Recurrent Genital Herpes.
Herpes Labialis
Solar simulator-induced herpes simplex labialis: use in evaluating treatment with acyclovir plus 348U87.
Herpes Simplex
2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir.
Herpes Simplex
2-Acetylpyridine thiocarbonohydrazones. Potent inactivators of herpes simplex virus ribonucleotide reductase.
Herpes Simplex
A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs.
Herpes Simplex
A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells.
Herpes Simplex
A monoclonal antibody against HSV type 1 ribonucleotide reductase cross-reacts with the P0 protein of peripheral nerve myelin.
Herpes Simplex
A novel gene expressed in human keratinocytes with long-term in vitro growth potential is required for cell growth.
Herpes Simplex
A novel human gene similar to the protein kinase (PK) coding domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) codes for a serine-threonine PK and is expressed in melanoma cells.
Herpes Simplex
A single amino acid substitution in the large subunit of herpes simplex virus type 1 ribonucleotide reductase which prevents subunit association.
Herpes Simplex
A solid-phase assay for the binding of peptidic subunit association inhibitors to the herpes simplex virus ribonucleotide reductase large subunit.
Herpes Simplex
A truncated protein kinase domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) expressed in Escherichia coli.
Herpes Simplex
Affinity of synthetic peptides for the HSV-2 ribonucleotide reductase R1 subunit measured with an iodinated photoaffinity peptide.
Herpes Simplex
Affinity purification of active subunit 1 of herpes simplex virus type 1 ribonucleotide reductase exhibiting a protein kinase activity.
Herpes Simplex
An autophosphorylating but not transphosphorylating activity is associated with the unique N terminus of the herpes simplex virus type 1 ribonucleotide reductase large subunit.
Herpes Simplex
An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy.
Herpes Simplex
Analysis of a herpes simplex virus 2 fragment from the open reading frame of the large subunit of ribonucleotide reductase with transcriptional regulatory activity.
Herpes Simplex
Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.
Herpes Simplex
Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase.
Herpes Simplex
Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
Herpes Simplex
AP-1 cis-response elements are involved in basal expression and Vmw110 transactivation of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).
Herpes Simplex
ATP and SH3 binding sites in the protein kinase of the large subunit of herpes simplex virus type 2 of ribonucleotide reductase (ICP10).
Herpes Simplex
Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.
Herpes Simplex
Can ribonucleotide reductase be considered as an effective target for developing antiherpes simplex virus type II (HSV-2) compounds?
Herpes Simplex
Characterization of heterosubunit complexes formed by the R1 and R2 subunits of herpes simplex virus 1 and equine herpes virus 4 ribonucleotide reductase.
Herpes Simplex
Characterization of ribonucleotide reductase induction in BHK-21/C13 Syrian hamster cell line upon infection by herpes simplex virus (HSV).
Herpes Simplex
Characterization of the novel protein kinase activity present in the R1 subunit of herpes simplex virus ribonucleotide reductase.
Herpes Simplex
Cloning of a ribonucleotide reductase gene of the herpes simplex virus type 2 strain G.
Herpes Simplex
Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.
Herpes Simplex
Crystal structure of the B subunit of Escherichia coli heat-labile enterotoxin carrying peptides with anti-herpes simplex virus type 1 activity.
Herpes Simplex
Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation.
Herpes Simplex
Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo.
Herpes Simplex
Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro.
Herpes Simplex
Deoxyribonucleoside triphosphate pools in synchronized human cells infected with herpes simplex virus types 1 and 2.
Herpes Simplex
Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK.
Herpes Simplex
Disruption of herpes simplex virus ribonucleotide reductase quaternary structure by peptide inhibitors as a novel approach to antiviral therapy.
Herpes Simplex
DNA amplification and neoplastic transformation mediated by a herpes simplex DNA fragment containing cell-related sequences.
Herpes Simplex
Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Herpes Simplex
Effect of siRNA on HSV-1 plaque formation and relative expression levels of UL39 mRNA.
Herpes Simplex
Effects of ribonucleotide reductase inhibition on pyrimidine deoxynucleotide metabolism in acyclovir-treated cells infected with herpes simplex virus type 1.
Herpes Simplex
Efficient extracellular production of hybrid E. coli heat-labile enterotoxin B subunits in a marine Vibrio.
Herpes Simplex
Enhanced malignant transformation induced by expression of a distinct protein domain of ribonucleotide reductase large subunit from herpes simplex virus type 2.
Herpes Simplex
Epitope mapping identifies an exposed loop between the unique amino- and conserved carboxy-domains of the large subunit of herpes simplex virus type 1 ribonucleotide reductase.
Herpes Simplex
Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease.
Herpes Simplex
Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model.
Herpes Simplex
Expression of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for virus growth and neoplastic transformation.
Herpes Simplex
Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant.
Herpes Simplex
Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus.
Herpes Simplex
Genomic sequences homologous to the protein kinase region of the bifunctional herpes simplex virus type 2 protein ICP10.
Herpes Simplex
Herpes simplex type 1 ribonucleotide reductase. Mechanism studies with inhibitors.
Herpes Simplex
Herpes Simplex Virus 1 (HSV-1) and HSV-2 Mediate Species-Specific Modulations of Programmed Necrosis through the Viral Ribonucleotide Reductase Large Subunit R1.
Herpes Simplex
Herpes simplex virus ribonucleotide reductase induced in infected BHK-21/C13 cells: biochemical evidence for the existence of two non-identical subunits, H1 and H2.
Herpes Simplex
Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir.
Herpes Simplex
Herpes simplex virus ribonucleotide reductase subunit association inhibitors: the effect and conformation of beta-alkylated aspartic acid derivatives.
Herpes Simplex
Herpes simplex virus ribonucleotide reductase: expression in Escherichia coli and purification to homogeneity of a tyrosyl free radical-containing, enzymatically active form of the 38-kilodalton subunit.
Herpes Simplex
Herpes simplex virus specifies two subunits of ribonucleotide reductase encoded by 3'-coterminal transcripts.
Herpes Simplex
Herpes simplex virus type 1 ribonucleotide reductase large subunit: regions of the protein essential for subunit interaction and dimerization.
Herpes Simplex
Herpes simplex virus type 1 ribonucleotide reductase null mutants induce lesions in guinea pigs.
Herpes Simplex
Herpes simplex virus type 1 ribonucleotide reductase: selective and synergistic inactivation by A1110U and its iron complex.
Herpes Simplex
Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.
Herpes Simplex
Herpes simplex virus type 2 growth and latency reactivation by cocultivation are inhibited with antisense oligonucleotides complementary to the translation initiation site of the large subunit of ribonucleotide reductase (RR1).
Herpes Simplex
Herpes simplex virus type 2: unique biological properties include neoplastic potential mediated by the PK domain of the large subunit of ribonucleotide reductase.
Herpes Simplex
Herpes simplex virus-encoded ribonucleotide reductase: evidence for the dissociation/reassociation of the holoenzyme.
Herpes Simplex
Herpes simplex virus-induced ribonucleotide reductase: development of antibodies specific for the enzyme.
Herpes Simplex
High level expression in 293 cells of the herpes simplex virus type 2 ribonucleotide reductase subunit 2 using an adenovirus vector.
Herpes Simplex
Identification and characterization of an extracellular protease activity produced by the marine Vibrio sp. 60.
Herpes Simplex
Identification and separation of the two subunits of the herpes simplex virus ribonucleotide reductase.
Herpes Simplex
Identification of a herpes simplex virus type 1 polypeptide which is a component of the virus-induced ribonucleotide reductase.
Herpes Simplex
Identification of immediate-early-type cis-response elements in the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2.
Herpes Simplex
Identification of ribonucleotide reductase mutation causing temperature-sensitivity of herpes simplex virus isolates from whitlow by deep sequencing.
Herpes Simplex
Identification of structural domains within the large subunit of herpes simplex virus ribonucleotide reductase.
Herpes Simplex
Identification of viral polypeptides involved in pseudorabies virus ribonucleotide reductase activity.
Herpes Simplex
Immediate early and functional AP-1 cis-response elements are involved in the transcriptional regulation of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).
Herpes Simplex
Immunological characterization of herpes simplex virus type 1 and 2 polypeptide(s) involved in viral ribonucleotide reductase activity.
Herpes Simplex
Improved adenovirus vector provides herpes simplex virus ribonucleotide reductase R1 and R2 subunits very efficiently.
Herpes Simplex
Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
Herpes Simplex
Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette.
Herpes Simplex
Inhibition of equine herpesvirus type 1 subtype 1-induced ribonucleotide reductase by the nonapeptide YAGAVVNDL.
Herpes Simplex
Inhibition of herpes simplex virus ribonucleotide reductase by synthetic nonapeptides: a potential antiviral therapy.
Herpes Simplex
Inhibition of herpes simplex virus type 1 ribonucleotide reductase by substituted tetrapeptide derivatives.
Herpes Simplex
Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: ribonucleotide reductase maturation as a probe of intracellular iron pools.
Herpes Simplex
Intracellular localisation of herpes simplex virus type 1 ribonucleotide reductase subunits during infection of cultured cells.
Herpes Simplex
Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase.
Herpes Simplex
Is ribonucleotide reductase the transforming function of herpes simplex virus 2?
Herpes Simplex
Leucine repeats in the large subunit of herpes simplex virus type 2 ribonucleotide reductase (RR; ICP10) are involved in RR activity and subunit complex formation.
Herpes Simplex
Localization and comparative nucleotide sequence analysis of the transforming domain in herpes simplex virus DNA containing repetitive genetic elements.
Herpes Simplex
Localization of the antigenic sites and intrinsic protein kinase domain within a 300 amino acid segment of the ribonucleotide reductase large subunit from herpes simplex virus type 2.
Herpes Simplex
Mechanism of inhibition of herpes simplex virus (HSV) ribonucleotide reductase by a nonapeptide corresponding to the carboxyl terminus of its subunit 2. Specific binding of a photoaffinity analog, [4'- azido-Phe6] HSV H2-6(6-15), to subunit 1.
Herpes Simplex
Mechanism of ribonucleotide reductase from herpes simplex virus type 1. Evidence for 3' carbon-hydrogen bond cleavage and inactivation by nucleotide analogs.
Herpes Simplex
Monoclonal antibody to HSV2 protein as an immunodiagnostic marker in cervical cancer.
Herpes Simplex
Myristylation and polylysine-mediated activation of the protein kinase domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).
Herpes Simplex
Neutralization of herpes simplex virus ribonucleotide reductase activity by an oligopeptide-induced antiserum directed against subunit H2.
Herpes Simplex
Oligopeptides inhibit the ribonucleotide reductase of herpes simplex virus by causing subunit separation.
Herpes Simplex
Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas.
Herpes Simplex
Papillomavirus trans-activator protein E2 activates expression from the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2.
Herpes Simplex
Partial purification and characterization of the ribonucleotide reductase induced by herpes simplex virus infection of mammalian cells.
Herpes Simplex
Partial Purification and Characterization of the Ribonucleotide Reductase Induced by Herpes Simplex Virus Infection of Mammalian Cells.
Herpes Simplex
Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity.
Herpes Simplex
Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: a new class of antiviral agents.
Herpes Simplex
Performance and use of a ribonucleotide reductase herpes simplex virus type-specific serological assay.
Herpes Simplex
Polymorphism within the herpes simplex virus (HSV) ribonucleotide reductase large subunit (ICP6) confers type specificity for recognition by HSV type 1-specific cytotoxic T lymphocytes.
Herpes Simplex
Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.
Herpes Simplex
Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition.
Herpes Simplex
Production of the R2 subunit of ribonucleotide reductase from herpes simplex virus with prokaryotic and eukaryotic expression systems: higher activity of R2 produced by eukaryotic cells related to higher iron-binding capacity.
Herpes Simplex
Protein kinase activity associated with the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).
Herpes Simplex
Purification and characterization of recombinant mouse and herpes simplex virus ribonucleotide reductase R2 subunit.
Herpes Simplex
Purification and characterization of the herpes simplex virus type 1 ribonucleotide reductase small subunit following expression in Escherichia coli.
Herpes Simplex
Radiation inactivation of ribonucleotide reductase, an enzyme with a stable free radical.
Herpes Simplex
Reconstitution of herpes simplex virus type 1 ribonucleotide reductase activity from the large and small subunits.
Herpes Simplex
Reduction of the tyrosyl radical and the iron center in protein R2 of ribonucleotide reductase from mouse, herpes simplex virus and E. coli by p-alkoxyphenols.
Herpes Simplex
Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.
Herpes Simplex
Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates.
Herpes Simplex
Retention and expression of the left end subfragment of the herpes simplex virus type 2 BglII N DNA fragment do not correlate with tumorigenic conversion of NIH 3T3 cells.
Herpes Simplex
Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus.
Herpes Simplex
Ribonucleotide reductase activity of synchronized KB cells infected with herpes simplex virus.
Herpes Simplex
Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target.
Herpes Simplex
Ribonucleotide reductase from herpes simplex virus (types 1 and 2) infected and uninfected KB cells: properties of the partially purified enzymes.
Herpes Simplex
Ribonucleotide reductase induced by herpes simplex type 1 virus. Characterization of a distinct enzyme.
Herpes Simplex
Ribonucleotide reductase induced by herpes simplex virus has a virus-specified constituent.
Herpes Simplex
Ribonucleotide reductase induced by varicella zoster virus. Characterization, and potentiation of acyclovir by its inhibition.
Herpes Simplex
Ribonucleotide reductase of herpes simplex virus type 2 resembles that of herpes simplex virus type 1.
Herpes Simplex
Ribonucleotide reductase: an important enzyme in the replication of herpes simplex virus type 1 and a target for antiviral chemotherapy.
Herpes Simplex
RNA interference inhibits herpes simplex virus type 1 isolated from saliva samples and mucocutaneous lesions.
Herpes Simplex
Role of viral ribonucleotide reductase in the increase of dTTP pool size in herpes simplex virus-infected Vero cells.
Herpes Simplex
Search for multienzyme complexes of DNA precursor pathways in uninfected mammalian cells and in cells infected with herpes simplex virus type I.
Herpes Simplex
Sequence analysis of the UL39, UL38, and UL37 homologues of bovine herpesvirus 1 and expression studies of UL40 and UL39, the subunits of ribonucleotide reductase.
Herpes Simplex
Specific inhibition of herpes virus replication by receptor-mediated entry of an antiviral peptide linked to Escherichia coli enterotoxin B subunit.
Herpes Simplex
Specific inhibition of herpesvirus ribonucleotide reductase by a nonapeptide derived from the carboxy terminus of subunit 2.
Herpes Simplex
Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides.
Herpes Simplex
Stress up-regulates neuronal expression of the herpes simplex virus type 2 large subunit of ribonucleotide reductase (R1; ICP10) by activating activator protein 1.
Herpes Simplex
Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.
Herpes Simplex
Structure-function studies of peptides inhibiting the ribonucleotide reductase activity of herpes simplex virus type I.
Herpes Simplex
Study of ribonucleotide reductase in cells infected with six clinical isolates of herpes simplex virus type 2 (HSV-2) with mutations in its larger subunit.
Herpes Simplex
Susceptibility of a herpes simplex virus ribonucleotide reductase null mutant to deoxyribonucleosides and antiviral nucleoside analogs.
Herpes Simplex
Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice.
Herpes Simplex
Synthesis and inhibitory potency of peptides corresponding to the subunit 2 C-terminal region of herpes virus ribonucleotide reductases.
Herpes Simplex
The 140-kDa RR1 protein from both HSV-1 and HSV-2 contains an intrinsic protein kinase activity capable of autophosphorylation but it is transphosphorylation defective.
Herpes Simplex
The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture.
Herpes Simplex
The bovine viral diarrhea virus (BVDV) NS3 protein, when expressed alone in mammalian cells, induces apoptosis which correlates with caspase-8 and caspase-9 activation.
Herpes Simplex
The critical C-terminus of the small subunit of herpes simplex virus ribonucleotide reductase is mobile and conformationally similar to C-terminal peptides.
Herpes Simplex
The effects of interferon-alpha and acyclovir on herpes simplex virus type-1 ribonucleotide reductase.
Herpes Simplex
The equine arteritis virus induces apoptosis via caspase-8 and mitochondria-dependent caspase-9 activation.
Herpes Simplex
The herpes simplex virus ribonucleotide reductase is required for ocular virulence.
Herpes Simplex
The herpes simplex virus type 1 ICP6 gene is regulated by a 'leaky' early promoter.
Herpes Simplex
The herpes simplex virus type 1 ribonucleotide reductase is a tight complex of the type alpha 2 beta 2 composed of 40K and 140K proteins, of which the latter shows multiple forms due to proteolysis.
Herpes Simplex
The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease.
Herpes Simplex
The herpes simplex virus type 1 temperature-sensitive mutant ts1222 has a single base pair deletion in the small subunit of ribonucleotide reductase.
Herpes Simplex
The herpes simplex virus type 2 gene which encodes the large subunit of ribonucleotide reductase has unusual regulatory properties.
Herpes Simplex
The hsv-2 la-1 oncoprotein is a member of a novel family of serine threonine receptor kinases.
Herpes Simplex
The large subunit of herpes simplex virus type 1 ribonucleotide reductase: expression in Escherichia coli and purification.
Herpes Simplex
The large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is associated with the virion tegument and has PK activity.
Herpes Simplex
The novel protein kinase of the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2.
Herpes Simplex
The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice.
Herpes Simplex
The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth.
Herpes Simplex
The principal hydrogen donor for the herpes simplex virus type 1-encoded ribonucleotide reductase in infected cells is a cellular thioredoxin.
Herpes Simplex
The protein kinase activity of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) fused to the extracellular domain of the epidermal growth factor receptor is ligand-inducible.
Herpes Simplex
The R1 subunit of herpes simplex virus ribonucleotide reductase has chaperone-like activity similar to Hsp27.
Herpes Simplex
The R1 subunit of herpes simplex virus ribonucleotide reductase is a good substrate for host cell protein kinases but is not itself a protein kinase.
Herpes Simplex
The R1 subunit of herpes simplex virus ribonucleotide reductase protects cells against apoptosis at, or upstream of, caspase-8 activation.
Herpes Simplex
The ribonucleotide reductase domain of the R1 subunit of herpes simplex virus type 2 ribonucleotide reductase is essential for R1 antiapoptotic function.
Herpes Simplex
The ribonucleotide reductase induced by herpes simplex virus type 1 involves minimally a complex of two polypeptides (136K and 38K).
Herpes Simplex
The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection.
Herpes Simplex
The Ribonucleotide Reductase R1 Subunits of Herpes Simplex Virus 1 and 2 Protect Cells against Poly(I {middle dot} C)-Induced Apoptosis.
Herpes Simplex
The ribonucleotide reductase R1 subunits of herpes simplex virus types 1 and 2 protect cells against TNF?- and FasL-induced apoptosis by interacting with caspase-8.
Herpes Simplex
The role of herpes simplex virus ribonucleotide reductase small subunit carboxyl terminus in subunit interaction and formation of iron-tyrosyl center structure.
Herpes Simplex
The RR1 gene of herpes simplex virus type 1 is uniquely trans activated by ICP0 during infection.
Herpes Simplex
The small subunit of ribonucleotide reductase is encoded by one of the most abundant translationally regulated maternal RNAs in clam and sea urchin eggs.
Herpes Simplex
The transmembrane domain of the large subunit of HSV-2 ribonucleotide reductase (ICP10) is required for protein kinase activity and transformation-related signaling pathways that result in ras activation.
Herpes Simplex
The transmembrane helical segment but not the invariant lysine is required for the kinase activity of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).
Herpes Simplex
The UL5 gene of herpes simplex virus type 1: isolation of a lacZ insertion mutant and association of the UL5 gene product with other members of the helicase-primase complex.
Herpes Simplex
The unique N terminus of herpes simplex virus type 1 ribonucleotide reductase large subunit is phosphorylated by casein kinase 2, which may have a homologue in Escherichia coli.
Herpes Simplex
The unique N terminus of the herpes simplex virus type 1 large subunit is not required for ribonucleotide reductase activity.
Herpes Simplex
The unique N-terminal domain of the large subunit of herpes simplex virus ribonucleotide reductase is preferentially sensitive to proteolysis.
Herpes Simplex
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.
Herpes Simplex
Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir.
Herpes Simplex
Understanding the molecular mechanism of viral resistance to peptidomimetic inhibitors of ribonucleotide reductase.
Herpes Simplex
Ureido-based peptidomimetic inhibitor of herpes simplex virus ribonucleotide reductase: an investigation of inhibitor bioactive conformation.
Herpes Simplex
Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10).
Herpes Simplex
[Characteristics and physical mapping of the gene of the herpes simplex virus that controls ribonucleotide reductase activity]
Herpes Simplex
[The relationship between gene function and virulence in alpha-herpesviruses]
Herpes Zoster
Ribonucleotide reductase induced by varicella zoster virus. Characterization, and potentiation of acyclovir by its inhibition.
Herpes Zoster
Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice.
Huntington Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Hydatidiform Mole
[Changes in gene expression profiles of hydatidiform mole and choriocarcinoma as compared with trophoblast hyperplasia]
Hypersensitivity
Effect of deoxyribonucleosides on the hypersensitivity of human peripheral blood lymphocytes to UV-B and UV-C irradiation.
Hypersensitivity
Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir.
Hypersensitivity
Involvement of the PP2C-like phosphatase Ptc2p in the DNA checkpoint pathways of Saccharomyces cerevisiae.
Hypersensitivity
Susceptibility of a herpes simplex virus ribonucleotide reductase null mutant to deoxyribonucleosides and antiviral nucleoside analogs.
Infections
A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells.
Infections
A single point mutation in class III ribonucleotide reductase promoter renders Pseudomonas aeruginosa PAO1 inefficient for anaerobic growth and infection.
Infections
Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.
Infections
Antibacterial activity of radical scavengers against class Ib ribonucleotide reductase from Bacillus anthracis.
Infections
Characterization of ribonucleotide reductase induction in BHK-21/C13 Syrian hamster cell line upon infection by herpes simplex virus (HSV).
Infections
Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
Infections
Correction for Dreux et al., Ribonucleotide Reductase Repressor NrdR as a Novel Regulator for Motility and Chemotaxis during Adherent-Invasive Escherichia coli Infection.
Infections
Direct activation of RIP3/MLKL-dependent necrosis by herpes simplex virus 1 (HSV-1) protein ICP6 triggers host antiviral defense.
Infections
Expression of the HSV-2 ribonucleotide reductase subunits in adenovirus vectors or stably transformed cells: restoration of enzymatic activity by reassociation of enzyme subunits in the absence of other HSV proteins.
Infections
Feedback inhibition of bovine herpesvirus 5 replication by dual-copy bhv5-miR-B10-3p.
Infections
Herpes simplex virus ribonucleotide reductase: expression in Escherichia coli and purification to homogeneity of a tyrosyl free radical-containing, enzymatically active form of the 38-kilodalton subunit.
Infections
Identification of a second functional glutaredoxin encoded by the bacteriophage T4 genome.
Infections
In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.
Infections
In vivo function of the Murid Herpesvirus-4 ribonucleotide reductase small subunit.
Infections
Induction of a new ribonucleotide reductase after infection of mouse L cells with pseudorabies virus.
Infections
Induction of ribonucleotide reductase activity in cells infected with African swine fever virus.
Infections
Intracellular localisation of herpes simplex virus type 1 ribonucleotide reductase subunits during infection of cultured cells.
Infections
Intron-containing T4 bacteriophage gene sunY encodes an anaerobic ribonucleotide reductase.
Infections
Leishmania induces survival, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration of HIV co-infection.
Infections
Multiplex PCR for the diagnosis of red sea bream iridoviruses isolated in Korea.
Infections
NrdH-redoxin mediates high enzyme activity in manganese-reconstituted ribonucleotide reductase from Bacillus anthracis.
Infections
Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus.
Infections
Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.
Infections
Ribonucleotide reductase from herpes simplex virus (types 1 and 2) infected and uninfected KB cells: properties of the partially purified enzymes.
Infections
Ribonucleotide reductase NrdR as a novel regulator for motility and chemotaxis during adherent-invasive Escherichia coli infection.
Infections
Ribonucleotide reductase of herpes simplex virus type 2 resembles that of herpes simplex virus type 1.
Infections
Ribonucleotide reductase of shrimp white spot syndrome virus (WSSV): expression and enzymatic activity in a baculovirus/insect cell system and WSSV-infected shrimp.
Infections
Roles of vaccinia virus ribonucleotide reductase and glutaredoxin in DNA precursor biosynthesis.
Infections
Shift in ribonucleotide reductase gene expression in Pseudomonas aeruginosa during infection.
Infections
Synergistic antiviral action of ribonucleotide reductase inhibitors and 3'-azido-3'-deoxythymidine on HIV type 1 infection in vitro.
Infections
T4 phage ribonucleotide reductase. Allosteric regulation in vivo by thymidine triphosphate.
Infections
The early expression of glycoprotein B from herpes simplex virus can be detected by antigen-specific CD8+ T cells.
Infections
The herpes simplex virus ribonucleotide reductase is required for ocular virulence.
Infections
The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection.
Infections
Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir.
Infections
Transcriptional analysis of the white spot syndrome virus major virion protein genes.
Infections
Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation.
Infections
Unusual regulation of expression of the herpes simplex virus DNA polymerase gene.
Infections
Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10).
Infections
Vaccinia virus-induced ribonucleotide reductase can be distinguished from host cell activity.
Infections
Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir.
Iron Deficiencies
The yeast Aft1 transcription factor activates ribonucleotide reductase catalytic subunit RNR1 in response to iron deficiency.
Iron Deficiencies
Yeast Dun1 kinase regulates ribonucleotide reductase inhibitor Sml1 in response to iron deficiency.
Iron Deficiencies
Yeast Dun1 Kinase Regulates Ribonucleotide Reductase Small Subunit Localization in Response to Iron Deficiency.
Kidney Neoplasms
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
Latent Infection
A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells.
Leprosy
Ribonucleotide reductase as a drug target against drug resistance Mycobacterium leprae: A molecular docking study.
Leukemia
3-Chloro-N'-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy.
Leukemia
A LC-MS/MS Method for the Analysis of Intracellular Nucleoside Triphosphate Levels.
Leukemia
A novel N-hydroxy-N'-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C).
Leukemia
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.
Leukemia
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Leukemia
Amidox, an inhibitor of ribonucleotide reductase, potentiates the action of Ara-C in HL-60 human promyelocytic leukemia cells.
Leukemia
Analysis of the in vitro inhibition of murine and human tumor cell growth by pyrazole derivatives and a substituted azabicyclo [3.1.0] hexane-2,4-dione.
Leukemia
Antitumor effects of biologic reducing agents related to 3,4-dihydroxybenzylamine: dihydroxybenzaldehyde, dihydroxybenzaldoxime, and dihydroxybenzonitrile.
Leukemia
Avemar, a nontoxic fermented wheat germ extract, induces apoptosis and inhibits ribonucleotide reductase in human HL-60 promyelocytic leukemia cells.
Leukemia
Biochemical modulation of Ara-C effects by amidox, an inhibitor of ribonucleotide reductase in HL-60 promyelocytic human leukemia cells.
Leukemia
Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.
Leukemia
Cell-cycle associated transcriptional regulation of ribonucleotide reductase in L1210 leukemia cells and drug-resistant variants.
Leukemia
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.
Leukemia
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
Leukemia
Clinical toxic effects of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY) with relevant pharmacokinetic parameters.
Leukemia
Clofarabine Has Apoptotic Effect on T47D Breast Cancer Cell Line via P53R2 Gene Expression.
Leukemia
Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
Leukemia
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
Leukemia
Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.
Leukemia
Effect of the solvent-dependent conformational system of hydroxyureas on predicted vs. observed log P.
Leukemia
Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia.
Leukemia
Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells.
Leukemia
Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.
Leukemia
In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
Leukemia
Inhibition of ribonucleotide reductase, DNA synthesis, and L1210 leukemia by guanazole.
Leukemia
Leukocyte ribonucleotide reductase: studies in normal subjects and in subjects with leukemia or pernicious anemia.
Leukemia
N-hydroxy-N'-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: Synergistic antitumor activity with arabinofuranosylcytosine.
Leukemia
Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase.
Leukemia
Overexpression of thioredoxin in Fanconi anemia fibroblasts prevents the cytotoxic and DNA damaging effect of mitomycin C and diepoxybutane.
Leukemia
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Leukemia
Potentiation of 2',3'-dideoxycytidine (ddC) by hydroxyurea and thymidine on the Moloney murine leukemia virus (MoMLV) early replicative steps.
Leukemia
Resveratrol, an ingredient of wine, acts synergistically with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells.
Leukemia
Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo.
Leukemia
The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase.
Leukemia
The ribonucleotide reductase inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells.
Leukemia
Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis.
Leukemia
Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Leukemia
Trimidox, an inhibitor of ribonucleotide reductase, induces apoptosis and activates caspases in HL-60 promyelocytic leukemia cells.
Leukemia
Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells.
Leukemia L1210
Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Leukemia L1210
Altered sensitivity of deoxyadenosine-resistant mouse leukemia L1210 cells to various kinase inhibitors.
Leukemia L1210
Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine,wortmannin and UCN-01.
Leukemia L1210
Changes in messenger RNA levels for the subunits of ribonucleotide reductase during the cell cycle of leukemia L1210 cells.
Leukemia L1210
Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Leukemia L1210
Differential turnover of the subunits of ribonucleotide reductase in synchronized leukemia L1210 cells.
Leukemia L1210
Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.
Leukemia L1210
Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
Leukemia L1210
Effects of N-hydroxy-N'-aminoguanidine isoquinoline in combination with other inhibitors of ribonucleotide reductase on L1210 cells.
Leukemia L1210
Enhanced roscovitine-induced apoptosis is mediated by a caspase-3-like activity in deoxyadenosine-resistant mouse leukemia L1210 cells.
Leukemia L1210
In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
Leukemia L1210
Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells.
Leukemia L1210
Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives.
Leukemia L1210
Mouse leukemia L1210 cells selected for resistance to the ribonucleotide reductase inhibitor, 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone show altered response to DNA damaging agents.
Leukemia L1210
Overexpression of protein disulfide isomerase-like protein in a mouse leukemia L1210 cell line selected for resistance to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone, a ribonucleotide reductase inhibitor.
Leukemia L1210
Phenotypic changes in mouse leukemia L1210 cells with alterations in the effector-binding subunit of ribonucleotide reductase.
Leukemia L1210
Ribonucleotide reductase activity and growth of glutathione-depleted mouse leukemia L1210 cells in vitro.
Leukemia L1210
Structural aspects of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of L1210 cell growth and ribonucleotide reductase activity.
Leukemia L1210
Substituted 2-acylpyridine-alpha-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth.
Leukemia L1210
[Biochemical mechanisms of resistance to a new antineoplastic drug CRC 680578 from the nitrosourea class]
Leukemia P388
[Changes in the activity of thymidine kinase, ribonucleotide reductase and DNA-polymerases during the development of leukemia P388 in mice]
Leukemia, Erythroblastic, Acute
Regulation of DNA synthesis by the higher-order chromatin structure.
Leukemia, Lymphocytic, Chronic, B-Cell
DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib?based therapy.
Leukemia, Myeloid
Development of resistance to hydroxyurea during treatment of human myelogenous leukemia K562 cells with alpha-difluoromethylornithine as a result of coamplification of genes for ornithine decarboxylase and ribonucleotide reductase R2 subunit.
Leukemia, Myeloid
Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin.
Leukemia, Myeloid
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Leukemia, Myeloid, Acute
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Leukemia, Myeloid, Acute
CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
Leukemia, Myeloid, Acute
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase.
Leukemia, Myeloid, Acute
Phase I Study of GTI-2040, a Ribonucleotide Reductase Anti-Sense, with High Dose Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.
Leukemia, T-Cell
Overexpression of thioredoxin in Fanconi anemia fibroblasts prevents the cytotoxic and DNA damaging effect of mitomycin C and diepoxybutane.
Liver Neoplasms
[Apoptosis mechanism of taxol combined with resveratrol on human laryngeal carcinoma Hep-2 cells].
Liver Neoplasms, Experimental
Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells.
Liver Neoplasms, Experimental
Subcellular localization of ribonucleotide reductase in Novikoff hepatoma and regenerating rat liver.
Lung Neoplasms
(18)F-fluorodeoxyglucose Uptake with Expression of Excision Repair Cross-complementary Group 1 and Ribonucleotide Reductase Subunit M1 in Non-small Cell Lung Cancer.
Lung Neoplasms
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
Lung Neoplasms
Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer.
Lung Neoplasms
Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms.
Lung Neoplasms
Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Lung Neoplasms
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Lung Neoplasms
cRGD Grafted siRNA Nano-constructs for Chemosensitization of Gemcitabine Hydrochloride in Lung Cancer Treatment.
Lung Neoplasms
Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
Lung Neoplasms
ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Lung Neoplasms
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
Lung Neoplasms
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.
Lung Neoplasms
ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Lung Neoplasms
Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
Lung Neoplasms
Expression of RRM1 and its correlation with sensitivity to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
Lung Neoplasms
Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.
Lung Neoplasms
Fusion of Quantitative Image and Genomic Biomarkers to Improve Prognosis Assessment of Early Stage Lung Cancer Patients.
Lung Neoplasms
Growth pattern analysis of murine lung neoplasms by advanced semi-automated quantification of micro-CT images.
Lung Neoplasms
Identification of prognostic markers of lung cancer through bioinformatics analysis and in vitro experiments.
Lung Neoplasms
In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy.
Lung Neoplasms
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.
Lung Neoplasms
Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1).
Lung Neoplasms
Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer.
Lung Neoplasms
Molecular predictors of response to chemotherapy in non-small cell lung cancer.
Lung Neoplasms
Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations.
Lung Neoplasms
mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.
Lung Neoplasms
Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy.
Lung Neoplasms
P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer.
Lung Neoplasms
Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer.
Lung Neoplasms
Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.
Lung Neoplasms
Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
Lung Neoplasms
Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
Lung Neoplasms
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Lung Neoplasms
Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer.
Lung Neoplasms
Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
Lung Neoplasms
Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: A meta-analysis.
Lung Neoplasms
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Lung Neoplasms
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
Lung Neoplasms
RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Lung Neoplasms
RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine.
Lung Neoplasms
RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum.
Lung Neoplasms
Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
Lung Neoplasms
The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
Lung Neoplasms
The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival.
Lung Neoplasms
[Differential expressions of MDR-1, RRM-1, EGFR and ERCC-1 in primary tumors and metastatic lymph nodes of NSCLC patients].
Lung Neoplasms
[Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and ?-tubulin3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy]
Lung Neoplasms
[Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines]
Lung Neoplasms
[Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients].
Lymphadenitis
[SATB1 promotes the malignant of human non-Hodgkin lymphoma by activating the ribonucleotide reductase ?small subunit M2].
Lymphatic Metastasis
Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
Lymphatic Metastasis
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Lymphoma
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
Lymphoma
Analysis of proliferating cell fraction determined by monoclonal antibody to M1-subunit ribonucleotide reductase and Ki-67 in relation to p53 protein expression in fine-needle aspirates from non-Hodgkin's lymphomas.
Lymphoma
Demonstration of normal and mutant protein M1 subunits of deoxyGTP-resistant ribonucleotide reductase from mutant mouse lymphoma cells.
Lymphoma
DeoxyATP-resistant ribonucleotide reductase of mutant mouse lymphoma cells. Evidence for heterozygosity for the protein M1 subunits.
Lymphoma
Effect of cyclic AMP on the cell cycle regulation of ribonucleotide reductase M2 subunit messenger RNA concentrations in wild-type and mutant S49 T lymphoma cells.
Lymphoma
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
Lymphoma
Intracellular deoxyribonucleotide pool imbalance and DNA damage in cells treated with hydroxyurea, an inhibitor of ribonucleotide reductase.
Lymphoma
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Lymphoma
Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
Lymphoma
Ribonucleotide reductase gene expression during cyclic AMP-induced cell cycle arrest in T lymphocytes.
Lymphoma
Ribonucleotide reductase in cultured mouse lymphoma cells. Cell cycle-dependent variation in the activity of subunit protein M2.
Lymphoma
Ribonucleotide Reductase Inhibitor 3-AP Induces Oncogenic Virus Infected Cell Death and Represses Tumor Growth.
Lymphoma
Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma.
Lymphoma, B-Cell
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Lymphoma, Large B-Cell, Diffuse
Increased level of ribonucleotide reductase in deoxyadenosine resistant adenosine deaminase deficient human histiocytic lymphoma cells.
Lymphoma, Mantle-Cell
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
Lymphoma, Non-Hodgkin
Comparison of the expression of human equilibrative nucleotide transporter 1 (hENT1) and ribonucleotide reductase subunit M1 (RRM1) genes in seven non-Hodgkin lymphoma cell lines.
Lymphoma, Non-Hodgkin
[SATB1 promotes the malignant of human non-Hodgkin lymphoma by activating the ribonucleotide reductase ?small subunit M2].
Lymphoma, Primary Effusion
Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma.
Lymphopenia
Resistance of an adenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation.
Malaria
Ribonucleotide reductase inhibitors with erythropoietin and iron sulfate against malaria.
Malaria, Vivax
[Determination of key interventions for the transition from control to elimination of malaria in China].
Marek Disease
Deletion of Marek's disease virus large subunit of ribonucleotide reductase impairs virus growth in vitro and in vivo.
Marek Disease
Identification and in vitro characterization of a Marek's disease virus-encoded Ribonucleotide reductase.
Mastocytoma
Control of ribonucleotide reductase in heat- and cold-sensitive mammalian cell-cycle mutants.
Medulloblastoma
Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
Melanoma
A novel human gene similar to the protein kinase (PK) coding domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) codes for a serine-threonine PK and is expressed in melanoma cells.
Melanoma
Bromodeoxyuridine mutagenesis, ribonucleotide reductase activity, and deoxyribonucleotide pools in hydroxyurea-resistant mutants.
Melanoma
Cytotoxic and biochemical effects of thymidine and 3-deazauridine on human tumor cells.
Melanoma
Resistance to bromodeoxyuridine mutagenesis and toxicity in mammalian cells selected for resistance to hydroxyurea.
Melanoma
Ribonucleotide reductase and thymidylate synthase or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion.
Melanoma
Ribonucleotide reductase in melanoma tissue. EPR detection in human amelanotic melanoma and quenching of the tyrosine radical by 4-hydroxyanisole.
Melanoma
siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide.
Melanoma, Amelanotic
Ribonucleotide reductase in melanoma tissue. EPR detection in human amelanotic melanoma and quenching of the tyrosine radical by 4-hydroxyanisole.
Melanoma, Experimental
Identification of 'non-proliferating' B16 melanoma cells using monoclonal antibody (AD203) against the M1 subunit of ribonucleotide reductase.
Meningioma
Long-term follow-up result of hydroxyurea chemotherapy for recurrent meningiomas.
Mesothelioma
Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.
Mesothelioma
Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Mesothelioma, Malignant
Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Mouth Neoplasms
Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway.
Multiple Myeloma
An in-silico approach to predict and exploit synthetic lethality in cancer metabolism.
Multiple Myeloma
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
Multiple Myeloma
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
Multiple Myeloma
[Expression of Ribonucleotide Reductase M2 in Patients with Multiple Myeloma and Its Mechanism Inhibiting Tumor Cell Proliferation].
Murine Acquired Immunodeficiency Syndrome
Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine.
Murine Acquired Immunodeficiency Syndrome
Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS).
Myeloproliferative Disorders
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Myeloproliferative Disorders
ATR activation necessary but not sufficient for p53 induction and apoptosis in hydroxyurea-hypersensitive myeloid leukemia cells.
Myeloproliferative Disorders
Metastatic squamous cell carcinoma of the skin in chronic myeloid leukaemia: complication of hydroxyurea therapy.
Myoma
[Active form of ribonucleotide reductase and level of free iron in human uterine myoma]
Myxoma
The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase.
Nasopharyngeal Carcinoma
Antibodies against the large subunit of the EBV-encoded ribonucleotide reductase in patients with nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Distribution of epstein-barr virus antigenic sites on the carboxyl terminal end of ribonucleotide reductase against nasopharyngeal carcinoma serum antibodies using an immunoabsorption method.
Nasopharyngeal Carcinoma
Enzyme-linked immunosorbent assay (ELISA) for IgA and IgG antibodies to Epstein-Barr-virus ribonucleotide reductase in patients with nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
p53R2 as a novel prognostic biomarker in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts.
Nasopharyngeal Neoplasms
Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity.
Neoplasm Metastasis
A small molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
Neoplasm Metastasis
An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.
Neoplasm Metastasis
Antitumor and radiosensitizing effects of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, a novel inhibitor of ribonucleoside diphosphate reductase, on human colon carcinoma xenografts in nude mice.
Neoplasm Metastasis
Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus.
Neoplasm Metastasis
Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial-mesenchymal transition.
Neoplasm Metastasis
Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
Neoplasm Metastasis
Lack of correlation between deoxyribonucleotide pool sizes, spontaneous mutation rates and malignant potential in Chinese hamster ovary cells.
Neoplasm Metastasis
Molecular genetic analysis of primary lung cancer and cancer metastatic to the lung.
Neoplasm Metastasis
Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
Neoplasm Metastasis
Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.
Neoplasm Metastasis
Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.
Neoplasm Metastasis
RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo.
Neoplasm Metastasis
The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones.
Neoplasm Metastasis
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.
Neoplasm Metastasis
Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy.
Neoplasm Metastasis
[Study of DNA microarray chip of associated genes of hydatidiform mole]
Neoplasms
5-aza-2',2'-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer.
Neoplasms
A cis-trans interaction at the 3'-untranslated region of ribonucleotide reductase mRNA is regulated by TGF-beta 1, TGF-beta 2, and TGF-beta 3.
Neoplasms
A comparison of ribonucleotide reductase activities in normal human fibroblast strains with their transformed counterparts.
Neoplasms
A dityrosyl-diiron radical cofactor center is essential for human ribonucleotide reductases.
Neoplasms
A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase.
Neoplasms
A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia.
Neoplasms
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
Neoplasms
A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.
Neoplasms
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Neoplasms
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
Neoplasms
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Neoplasms
A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer.
Neoplasms
A restriction cleavage and transfection system for introducing foreign DNA sequences into the genome of a herpesvirus.
Neoplasms
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage.
Neoplasms
A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts.
Neoplasms
A small molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
Neoplasms
Activity of the cytosolic isozyme of thymidine kinase in human primary lung tumors with reference to malignancy.
Neoplasms
Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report.
Neoplasms
Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent.
Neoplasms
Altered regulation of message stability and tumor promoter-responsive cis-trans interactions of ribonucleotide reductase R1 and R2 messenger RNAs in hydroxyurea-resistant cells.
Neoplasms
An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy.
Neoplasms
Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment.
Neoplasms
Association of Novel Gene Polymorphisms RRM1 -756T>C and -269 C>A With Breast Cancer.
Neoplasms
Association of the Genetic Polymorphisms RRM1 -756T>C and -269C>A With Cervical Neoplasia.
Neoplasms
Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.
Neoplasms
Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector.
Neoplasms
Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor.
Neoplasms
Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition.
Neoplasms
Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: mRNA stabilization, drug resistance, and malignancy (Review).
Neoplasms
Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment.
Neoplasms
Clinical evaluation of postoperative chemotherapy based on genetic testing in patients with stage IIIA non-small cell lung cancer.
Neoplasms
Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
Neoplasms
Cytotoxic and biochemical effects of 3,3',4,4',5,5'-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells.
Neoplasms
Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance.
Neoplasms
Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation.
Neoplasms
Defining a novel cis-element in the 3'-untranslated region of mammalian ribonucleotide reductase component R2 mRNA. cis-trans-interactions and message stability.
Neoplasms
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Neoplasms
Deoxynucleoside Salvage Facilitates DNA Repair During Ribonucleotide Reductase Blockade in Human Cervical Cancers.
Neoplasms
Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.
Neoplasms
Dibutyltin(IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes.
Neoplasms
Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IgE-mediated mast cell activation through attenuation of NF?B and AP-1 transcription.
Neoplasms
Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
Neoplasms
Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma.
Neoplasms
Digalloylresveratrol, a new phenolic acid derivative induces apoptosis and cell cycle arrest in human HT-29 colon cancer cells.
Neoplasms
Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells.
Neoplasms
Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival.
Neoplasms
Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells.
Neoplasms
Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine.
Neoplasms
E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
Neoplasms
Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
Neoplasms
Effects of N-hydroxy-N'-aminoguanidine derivatives on ribonucleotide reductase activity, nucleic acid synthesis, clonogenicity, and cell cycle of L1210 cells.
Neoplasms
Effects of the ferrous chelate of 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (MAIQ-1) on the kinetics of reduction of CDP by ribonucleotide reductase of the Novikoff tumor.
Neoplasms
Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers.
Neoplasms
Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia.
Neoplasms
Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Neoplasms
Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus.
Neoplasms
ESR studies on reactivity of protein-derived tyrosyl radicals formed by prostaglandin H synthase and ribonucleotide reductase.
Neoplasms
Evaluating the Therapeutic Potential of a Non-Natural Nucleotide that Inhibits Human Ribonucleotide Reductase.
Neoplasms
Evaluation of combinations of drugs that inhibit Ehrlich tumor cell ribonucleotide reductase.
Neoplasms
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.
Neoplasms
Evaluation of pseudorabies virus as a gene transfer vector and an oncolytic agent for human tumor cells.
Neoplasms
Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Neoplasms
Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial-mesenchymal transition.
Neoplasms
Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells.
Neoplasms
Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
Neoplasms
Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.
Neoplasms
Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.
Neoplasms
Fusion of Quantitative Image and Genomic Biomarkers to Improve Prognosis Assessment of Early Stage Lung Cancer Patients.
Neoplasms
Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase.
Neoplasms
Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors.
Neoplasms
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Neoplasms
GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.
Neoplasms
Growth pattern analysis of murine lung neoplasms by advanced semi-automated quantification of micro-CT images.
Neoplasms
GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.
Neoplasms
GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
Neoplasms
GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.
Neoplasms
High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
Neoplasms
Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis.
Neoplasms
Identification of F-box/LLR-repeated protein 17 as potential useful biomarker for breast cancer therapy.
Neoplasms
Identification of osalmid metabolic profile and active metabolites with anti-tumor activity in human hepatocellular carcinoma cells.
Neoplasms
Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles.
Neoplasms
Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools.
Neoplasms
In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
Neoplasms
In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
Neoplasms
Inactivation of ribonucleotide reductase in tumour cells and inhibition of tumour cell growth by p-alkoxyphenols.
Neoplasms
Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1.
Neoplasms
Inhibition of human cancer cell growth by inducible expression of human ribonucleotide reductase antisense cDNA.
Neoplasms
Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea.
Neoplasms
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.
Neoplasms
Inhibition of ribonucleotide reductase activity and nucleic acid synthesis in tumor cells by the dialdehyde derivatives of inosine (NSC 118994) and inosinic acid.
Neoplasms
Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives.
Neoplasms
Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide.
Neoplasms
Integrative Analysis Reveals Across-Cancer Expression Patterns and Clinical Relevance of Ribonucleotide Reductase in Human Cancers.
Neoplasms
Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells.
Neoplasms
Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group.
Neoplasms
Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Neoplasms
Iron and haem complexation studies of 2,3-dihydro-1H-imidazo(1,2-b)pyrazole (IMPY, NSC 51143), a tumour cell ribonucleotide reductase inhibitor.
Neoplasms
Iron binding capacity of didox (3,4 dihydroxybenzohydroxamic acid) and amidox (3,4 dihydroxybenzamidoxime) two inhibitors of the enzyme ribonucleotide reductase.
Neoplasms
Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase.
Neoplasms
Iron binding capacity of trimidox (3,4,5-trihydroxybenzamidoxime), a new inhibitor of the enzyme ribonucleotide reductase.
Neoplasms
Iron-targeting antitumor activity of gallium compounds and novel insights into Triapine®-metal complexes.
Neoplasms
Irreversible inhibition of ribonucleotide reductase from Ehrlich tumor cells by a modulator analog.
Neoplasms
Is ribonucleotide reductase in Ehrlich ascites mammary tumour cells the target of a growth inhibitor purified from bovine mammary gland?
Neoplasms
Lack of correlation between deoxyribonucleotide pool sizes, spontaneous mutation rates and malignant potential in Chinese hamster ovary cells.
Neoplasms
Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy.
Neoplasms
Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector.
Neoplasms
Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene.
Neoplasms
Mammalian ribonucleotide reductase R1 mRNA stability under normal and phorbol ester stimulating conditions: involvement of a cis-trans interaction at the 3' untranslated region.
Neoplasms
Mechanism for induction of hydroxyurea resistance and loss of latent EBV genome in hydroxyurea-treated Burkitt's lymphoma cell line Raji.
Neoplasms
Mechanism of action of key enzymes associated with cancer propagation and their inhibition by various chemotherapeutic agents.
Neoplasms
Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells.
Neoplasms
miR-211 regulates the expression of RRM2 in tumoral metastasis and recurrence in colorectal cancer patients with a k-ras gene mutation.
Neoplasms
Mode of inhibition of tumor cell ribonucleotide reductase by 2,3-dihydro-1H-pyrazolo[2,3-a]imidazole (NSC 51143).
Neoplasms
Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein.
Neoplasms
Molecular analysis-based treatment strategies for the management of non-small cell lung cancer.
Neoplasms
Molecular basis of the interaction of novel tributyltin(IV) 2/4-[(E)-2-(aryl)-1-diazenyl]benzoates endowed with an improved cytotoxic profile: synthesis, structure, biological efficacy and QSAR studies.
Neoplasms
Monoclonal antibody to HSV2 protein as an immunodiagnostic marker in cervical cancer.
Neoplasms
mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.
Neoplasms
Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Neoplasms
Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats.
Neoplasms
Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers.
Neoplasms
Neuroprotective activity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811), a cancer therapeutic agent.
Neoplasms
New Water-Soluble Copper(II) Complexes with Morpholine-Thiosemicarbazone Hybrids: Insights into the Anticancer and Antibacterial Mode of Action.
Neoplasms
Novel biological radiochemotherapy approaches in locally advanced-stage cervical cancer management.
Neoplasms
Novel Insights into Gallium's Mechanism of Therapeutic Action: A DFT/PCM Study of the Interaction between Ga3+ and Ribonucleotide Reductase Substrates.
Neoplasms
Novel Triapine Derivative Induces Copper-Dependent Cell Death in Hematopoietic Cancers.
Neoplasms
Osalmid, a Novel Identified RRM2 Inhibitor, Enhances Radiosensitivity of Esophageal Cancer.
Neoplasms
Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line.
Neoplasms
Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis.
Neoplasms
Overexpression of RRM2 in gastric cancer cell promotes their invasiveness via AKT/NF-?B signaling pathway.
Neoplasms
Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential.
Neoplasms
P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.
Neoplasms
p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest.
Neoplasms
P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer.
Neoplasms
PAN-811 Inhibits Oxidative Stress-Induced Cell Death of Human Alzheimer's Disease-Derived and Age-Matched Olfactory Neuroepithelial Cells Via Suppression of Intracellular Reactive Oxygen Species.
Neoplasms
Paracetamol inhibits replicative DNA synthesis and induces sister chromatid exchange and chromosomal aberrations by inhibition of ribonucleotide reductase.
Neoplasms
Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
Neoplasms
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Neoplasms
Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.
Neoplasms
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
Neoplasms
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Neoplasms
Phorbol ester modulation of a novel cytoplasmic protein binding activity at the 3'-untranslated region of mammalian ribonucleotide reductase R2 mRNA and role in message stability.
Neoplasms
Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy.
Neoplasms
Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule.
Neoplasms
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo.
Neoplasms
Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase.
Neoplasms
Potentiation of hydroxyurea cytotoxicity by iron-chelating agent in murine tumor models in vitro.
Neoplasms
Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
Neoplasms
Production of a monoclonal antibody against the hRRM2 subunit of ribonucleotide reductase and immunohistochemistry study of human cancer tissues.
Neoplasms
Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers.
Neoplasms
Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Neoplasms
Properties of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of mammalian ribonucleotide reductase.
Neoplasms
Properties of ribonucleotide reductase from Ehrlich tumor cells; multiple nucleoside diphosphate activities and reconstitution of activity from components.
Neoplasms
Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide. Relationship to cytostasis induced in tumor cells by cytotoxic macrophages.
Neoplasms
Quenching of tyrosine radicals of M2 subunit from ribonucleotide reductase in tumor cells by different antitumor agents: an EPR study.
Neoplasms
Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.
Neoplasms
Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers.
Neoplasms
Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis.
Neoplasms
Regulation of mammalian ribonucleotide reductase by the tumor promoters and protein phosphatase inhibitors okadaic acid and calyculin A.
Neoplasms
Response of human colon and prostate tumor xenografts to (E)-2'-deoxy-2'-(fluoromethylene) cytidine, an inhibitor of ribonucleotide reductase.
Neoplasms
Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?
Neoplasms
Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer.
Neoplasms
Ribonucleotide reductase activity in cell-free extracts of Yaba poxvirus tumor and normal monkey tissues.
Neoplasms
Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies.
Neoplasms
Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas.
Neoplasms
Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).
Neoplasms
Ribonucleotide reductase in ascites tumour cells detected by electron paramagnetic resonance spectroscopy.
Neoplasms
Ribonucleotide reductase in melanoma tissue. EPR detection in human amelanotic melanoma and quenching of the tyrosine radical by 4-hydroxyanisole.
Neoplasms
Ribonucleotide Reductase Inhibition Enhances Chemoradiosensitivity of Human Cervical Cancers.
Neoplasms
Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers.
Neoplasms
Ribonucleotide Reductase Inhibitor 3-AP Induces Oncogenic Virus Infected Cell Death and Represses Tumor Growth.
Neoplasms
Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization.
Neoplasms
Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
Neoplasms
Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
Neoplasms
Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Neoplasms
Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential.
Neoplasms
Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability.
Neoplasms
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Neoplasms
Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients.
Neoplasms
Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003.
Neoplasms
Ribonucleotide reductase subunit p53R2 regulates mitochondria homeostasis and function in KB and PC-3 cancer cells.
Neoplasms
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
Neoplasms
Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.
Neoplasms
Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents.
Neoplasms
Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.
Neoplasms
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Neoplasms
RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo.
Neoplasms
Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation.
Neoplasms
Role of ribonucleotide reductase in regulation of cell cycle progression during and after exposure to moderate hypoxia.
Neoplasms
RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Neoplasms
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
Neoplasms
RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness.
Neoplasms
RRM2 Regulated By LINC00667/miR-143-3p Signal Is Responsible For Non-Small Cell Lung Cancer Cell Progression.
Neoplasms
RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.
Neoplasms
RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway.
Neoplasms
Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7.
Neoplasms
Sequencing cyclic peptide inhibitors of mammalian ribonucleotide reductase by electrospray ionization mass spectrometry.
Neoplasms
Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
Neoplasms
siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide.
Neoplasms
SiRNA-Mediated RRM2 Gene Silencing Combined with Cisplatin in the Treatment of Epithelial Ovarian Cancer In Vivo: An Experimental Study of Nude Mice.
Neoplasms
Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.
Neoplasms
Specific inhibitors directed at the individual components of ribonucleotide reductase as an approach to combination chemotherapy.
Neoplasms
Stability and reactivation of tyrosine radicals from ribonucleotide reductase in tumor cells studied by ESR.
Neoplasms
Structure-based optimization of peptide inhibitors of mammalian ribonucleotide reductase.
Neoplasms
Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo.
Neoplasms
Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase.
Neoplasms
Studies of N-hydroxy-N'-aminoguanidine derivatives by nitrogen-15 nuclear magnetic resonance spectroscopy and as ribonucleotide reductase inhibitors.
Neoplasms
Studies on mammalian ribonucleotide reductase inhibition by pyridoxal phosphate and the dialdehyde derivatives of adenosine, adenosine 5'-monophosphate, and adenosine 5'-triphosphate.
Neoplasms
Substituted 2-acylpyridine-alpha-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth.
Neoplasms
Success and failure of dendritic cell (DC) anticancer activity may be modulated by nitric oxide synthetase (NOS) gene expression: a hypothesis.
Neoplasms
Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase.
Neoplasms
Suppression of malignancy by the 3' untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs.
Neoplasms
Synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia HL-60 cells.
Neoplasms
Synthesis and biological evaluation of O-alkylated tropolones and related alpha-ketohydroxy derivatives as ribonucleotide reductase inhibitors.
Neoplasms
Synthesis and evaluation of new salicylaldehyde-2-picolinylhydrazone Schiff base compounds of Ru(II), Rh(III) and Ir(III) as in vitro antitumor, antibacterial and fluorescence imaging agents.
Neoplasms
Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
Neoplasms
Synthesis of novel D- and L-3'-deoxy-3'-C-hydroxymethyl nucleoside with exocyclic methylene as potential ribonucleotide reductase inhibitor.
Neoplasms
Synthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenes.
Neoplasms
Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
Neoplasms
Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy.
Neoplasms
The 11p15.5 ribonucleotide reductase M1 subunit locus is not imprinted in Wilms' tumour and hepatoblastoma.
Neoplasms
The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle.
Neoplasms
The combination of ascorbate and menadione causes cancer cell death by oxidative stress and replicative stress.
Neoplasms
The effect of dinitrosyl iron complexes with glutathione and S-nitrosoglutathione on the development of experimental endometriosis in rats: a comparative studies.
Neoplasms
The effects of lithium in reversing hydroxyurea induced suppression of hematopoietic progenitor cells in vitro using retroviral infected long-term marrow cultures.
Neoplasms
The expression of ribonucleotide reductase m2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.
Neoplasms
The molecular weight of Ehrlich tumor cell ribonucleotide reductase and its subunits: effector-induced changes.
Neoplasms
The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer.
Neoplasms
The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments.
Neoplasms
The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones.
Neoplasms
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.
Neoplasms
The Ribonucleotide Reductase R1 Subunits of Herpes Simplex Virus 1 and 2 Protect Cells against Poly(I {middle dot} C)-Induced Apoptosis.
Neoplasms
The ribonucleotide reductase R1 subunits of herpes simplex virus types 1 and 2 protect cells against TNF?- and FasL-induced apoptosis by interacting with caspase-8.
Neoplasms
The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21.
Neoplasms
Thiosemicarbazone derivatives, thiazolyl hydrazones, effectively inhibit leukemic tumor cell growth: Down-regulation of ribonucleotide reductase activity and synergism with arabinofuranosylcytosine.
Neoplasms
Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo.
Neoplasms
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Neoplasms
Transcriptional responses to ionizing radiation reveal that p53R2 protects against radiation-induced mutagenesis in human lymphoblastoid cells.
Neoplasms
Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy.
Neoplasms
Transient elevation of ribonucleotide reductase activity, M2 mRNA and M2 protein in BALB/c 3T3 fibroblasts in the presence of 12-O-tetradecanoylphorbol-13-acetate.
Neoplasms
Triapine Derivatives Act as Copper Delivery Vehicles to Induce Deadly Metal Overload in Cancer Cells.
Neoplasms
Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells.
Neoplasms
Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients.
Neoplasms
Valproic acid sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2 hyperphosphorylation-mediated DNA repair pathway.
Neoplasms
Variation in the expression levels of predictive chemotherapy biomarkers in histological subtypes of lung adenocarcinoma: an immunohistochemical study of tissue samples.
Neoplasms
Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer.
Neoplasms
[Apoptosis mechanism of taxol combined with resveratrol on human laryngeal carcinoma Hep-2 cells].
Neoplasms
[Changes in ribonucleotide reductase activity in mouse leukemic cells and spleen during in vivo tumor growth and hydroxyurea administration]
Neoplasms
[Changes in the replication apparatus and phosphorus-containing metabolite pool in experimental tumors in animals during development]
Neoplasms
[Differential expressions of MDR-1, RRM-1, EGFR and ERCC-1 in primary tumors and metastatic lymph nodes of NSCLC patients].
Neoplasms
[Dinitrosyl iron complexes with glutathione recover rats with experimental endometriosis].
Neoplasms
[Expression of Ribonucleotide Reductase M2 in Patients with Multiple Myeloma and Its Mechanism Inhibiting Tumor Cell Proliferation].
Neoplasms
[Markers of the metabolic changes arising as a result of ionizing radiation exposure]
Neoplasms
[Non-clinical studies of gemcitabine--the mode of action and antitumor activities]
Neoplasms
[Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
Neoplasms
[Ribonucleotide reductase from a mammalian rat tumor (Zajdela's hepatoma): stereospecificity of the reduction]
Neoplasms
[Studies on the mechanism of cytotoxicity of 5-fluorouracil--through impairment of metabolism]
Neoplasms
[Studies on the thymidine-triphosphate synthesis in malignant tumors. I. Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis (author's trans)]
Neoplasms
[Studies on the thymidine-triphosphate synthesis in malignant tumors. II. Effect of hyperthermia, Vitamin K and Cytotoxic agents (author's transl)]
Neoplasms
[The EPR spectra of the ribonucleotide reductase in the tumorous tissues and organs of tumor-bearing animals]
Neural Tube Defects
Ribonucleotide reductase subunit R1: a gene conferring sensitivity to valproic acid-induced neural tube defects in mice.
Neurilemmoma
Treatment of Schwannomas with an Oncolytic Recombinant Herpes Simplex Virus in Murine Models of Neurofibromatosis Type 2.
Neurilemmoma
Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2.
Neuroblastoma
3-Chloro-N'-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy.
Neuroblastoma
Effect of adenosine analogues on protein carboxylmethyltransferase, S-adenosylhomocysteine hydrolase, and ribonucleotide reductase activity in murine neuroblastoma cells.
Neuroblastoma
Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group.
Neurofibrosarcoma
Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
Ovarian Neoplasms
Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Ovarian Neoplasms
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Ovarian Neoplasms
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ovarian Neoplasms
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.
Ovarian Neoplasms
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Ovarian Neoplasms
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
Ovarian Neoplasms
SiRNA-Mediated RRM2 Gene Silencing Combined with Cisplatin in the Treatment of Epithelial Ovarian Cancer In Vivo: An Experimental Study of Nude Mice.
Ovarian Neoplasms
Small Interfering RNA (siRNA)-Mediated Silencing of the M2 Subunit of Ribonucleotide Reductase: A Novel Therapeutic Strategy in Ovarian Cancer.
Ovarian Neoplasms
The High Expression of RRM2 Can Predict the Malignant Transformation of Endometriosis.
Pancreatic Neoplasms
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
Pancreatic Neoplasms
A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Pancreatic Neoplasms
Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells.
Pancreatic Neoplasms
CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
Pancreatic Neoplasms
Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine.
Pancreatic Neoplasms
Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
Pancreatic Neoplasms
Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis.
Pancreatic Neoplasms
Establishment of human pancreatic cancer gemcitabine?resistant cell line with ribonucleotide reductase overexpression.
Pancreatic Neoplasms
Expression of RRM1 and its correlation with sensitivity to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
Pancreatic Neoplasms
Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.
Pancreatic Neoplasms
Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Pancreatic Neoplasms
Hydroxyurea and trimidox enhance the radiation effect in human pancreatic adenocarcinoma cells.
Pancreatic Neoplasms
Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.
Pancreatic Neoplasms
In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy.
Pancreatic Neoplasms
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.
Pancreatic Neoplasms
Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
Pancreatic Neoplasms
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
Pancreatic Neoplasms
MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
Pancreatic Neoplasms
MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine based chemotherapy.
Pancreatic Neoplasms
miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.
Pancreatic Neoplasms
MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Pancreatic Neoplasms
Prediction of a Side Effect and Efficacy of Adjuvant Chemotherapy with Gemcitabine for Post Operative Patient of Pancreatic Cancer by a Genetic Polymorphism Analysis.
Pancreatic Neoplasms
Predictive and Prognostic Roles of Ribonucleotide Reductase M1 in Patients with Pancreatic Cancer Treated with Gemcitabine: A Meta-analysis.
Pancreatic Neoplasms
Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Pancreatic Neoplasms
Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer.
Pancreatic Neoplasms
Reversible epigenetic regulation of 14-3-3? expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1.
Pancreatic Neoplasms
Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
Pancreatic Neoplasms
Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Pancreatic Neoplasms
Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
Pancreatic Neoplasms
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Pancreatic Neoplasms
Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.
Pancreatic Neoplasms
Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
Parkinson Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Parkinson Disease
Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease.
Pneumonia
Molecular characterization of a ribonucleotide reductase (nrdF) gene fragment of Mycoplasma hyopneumoniae and assessment of the recombinant product as an experimental vaccine for enzootic pneumonia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effect of clofarabine on apoptosis and DNA synthesis in human epithelial colon cancer cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.
Prostatic Neoplasms
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
Prostatic Neoplasms
Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3.
Prostatic Neoplasms
Ribonucleotide reductase inhibition in the treatment of advanced prostate cancer: an experimental approach with hydroxyurea and gallium nitrate in 20 patients.
Prostatic Neoplasms
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Prostatic Neoplasms
The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Pseudorabies
Identification of interaction domains in the pseudorabies virus ribonucleotide reductase large and small subunits.
Pseudorabies
Identification of viral polypeptides involved in pseudorabies virus ribonucleotide reductase activity.
Pseudorabies
Induction of a new ribonucleotide reductase after infection of mouse L cells with pseudorabies virus.
Pseudorabies
Large and small subunits of the Aujeszky's disease virus ribonucleotide reductase: nucleotide sequence and putative structure.
Pseudorabies
Ribonucleotide reductase-deficient mutants of pseudorabies virus are avirulent for pigs and induce partial protective immunity.
Pseudorabies
Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides.
Pseudorabies
Structural features of the ribonucleotide reductase of Aujeszky's disease virus.
Pseudorabies
The herpes simplex virus type 1 ribonucleotide reductase is a tight complex of the type alpha 2 beta 2 composed of 40K and 140K proteins, of which the latter shows multiple forms due to proteolysis.
purine-nucleoside phosphorylase deficiency
Cockayne's syndrome fibroblasts are characterized by hypersensitivity to deoxyguanosine and abnormal DNA precursor pool metabolism in response to deoxyguanosine or ultraviolet light.
purine-nucleoside phosphorylase deficiency
Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP.
purine-nucleoside phosphorylase deficiency
The mechanism of inhibition and "reversal" of mitogen-induced lymphocyte activation in a model of purine-nucleoside phosphorylase deficiency.
Reperfusion Injury
Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators.
Respiratory Tract Infections
In vivo function of the Murid Herpesvirus-4 ribonucleotide reductase small subunit.
Retinal Diseases
The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease.
Retinoblastoma
Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model.
Retinoblastoma
The GpIA7 effector from the potato cyst nematode Globodera pallida targets potato EBP1 and interferes with the plant cell cycle programme.
Retinoblastoma
The GpIA7 effector from the potato cyst nematode Globodera pallida targets potato EBP1 and interferes with the plant cell cycle.
ribonucleoside-triphosphate reductase (thioredoxin) deficiency
Deoxynucleoside Salvage in Fission Yeast Allows Rescue of Ribonucleotide Reductase Deficiency but Not Spd1-Mediated Inhibition of Replication.
Sarcoma
The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase.
Sarcoma
[Nuclear ribonucleotide reductase of cells of normal regenerating liver and sarcoma M-1 in rats]
Sarcoma
[The ribonucleotide reductase activity of different structural elements of rat sarcoma M-1 cells]
Sarcoma, Ewing
Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Sarcoma, Ewing
Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.
Sarcoma, Ewing
mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells.
Seizures
Characterization of cell proliferation in the adult dentate under normal conditions and after kainate induced seizures using ribonucleotide reductase and BrdU.
Squamous Cell Carcinoma of Head and Neck
Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma.
Starvation
Activities of both ribonucleotide reductase subunits, M1 and M2, decrease upon serum starvation of baby hamster kidney 21/C13 cells.
Starvation
Cell cycle synchronization reveals greater G2/M-phase accumulation of lung epithelial cells exposed to titanium dioxide nanoparticles.
Starvation
Deoxyribonucleotide biosynthesis in yeast (Saccharomyces cerevisiae). A ribonucleotide reductase system of sufficient activity for DNA synthesis.
Starvation
In vitro and in vivo studies of a promising antileukemic thymidine analogue, 5-hydroxymethyl-2' deoxyuridine.
Starvation
Making DNA without iron - induction of a manganese-dependent ribonucleotide reductase in response to iron starvation.
Starvation
Regulation of the operon encoding ribonucleotide reductase in Escherichia coli: evidence for both positive and negative control.
Starvation
The alternative aerobic ribonucleotide reductase of Escherichia coli, NrdEF, is a manganese-dependent enzyme that enables cell replication during periods of iron starvation.
Starvation
The mechanism of inhibition and "reversal" of mitogen-induced lymphocyte activation in a model of adenosine deaminase deficiency.
Stomach Neoplasms
Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
Stomach Neoplasms
Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer.
Stomach Neoplasms
[Apoptosis mechanism of taxol combined with resveratrol on human laryngeal carcinoma Hep-2 cells].
Thyroid Cancer, Papillary
Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
Thyroid Neoplasms
Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
Triple Negative Breast Neoplasms
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Tuberculosis
A Dynamic C-Terminal Segment in the Mycobacterium tuberculosis Mn/Fe R2lox Protein Can Adopt a Helical Structure with Possible Functional Consequences.
Tuberculosis
Characterization of two genes encoding the Mycobacterium tuberculosis ribonucleotide reductase small subunit.
Tuberculosis
Crystal structure of the biologically active form of class Ib ribonucleotide reductase small subunit from Mycobacterium tuberculosis.
Tuberculosis
Design, synthesis and evaluation of peptide inhibitors of Mycobacterium tuberculosis ribonucleotide reductase.
Tuberculosis
EPR evidence of two structurally different diferric sites in Mycobacterium tuberculosis R2-2 ribonucleotide reductase protein.
Tuberculosis
Function and regulation of class I ribonucleotide reductase-encoding genes in mycobacteria.
Tuberculosis
Identification of small peptides mimicking the R2 C-terminus of Mycobacterium tuberculosis ribonucleotide reductase.
Tuberculosis
Isolation of ribonucleotide reductase from Mycobacterium tuberculosis and cloning, expression, and purification of the large subunit.
Tuberculosis
Low stability of the reduced state of Mycobacterium tuberculosis NrdH redoxin.
Tuberculosis
Novel pseudopeptides incorporating a benzodiazepine-based turn mimetic-targeting Mycobacterium tuberculosis ribonucleotide reductase.
Tuberculosis
Phototriggerable peptidomimetics for the inhibition of Mycobacterium tuberculosis ribonucleotide reductase by targeting protein-protein binding.
Tuberculosis
Reactivity studies of the tyrosyl radical in ribonucleotide reductase from Mycobacterium tuberculosis and Arabidopsis thaliana--comparison with Escherichia coli and mouse.
Tuberculosis
Ribonucleotide reduction in Mycobacterium tuberculosis: function and expression of genes encoding class Ib and class II ribonucleotide reductases.
Tuberculosis
Secondary structure conversions of Mycobacterium tuberculosis ribonucleotide reductase protein R2 under varying pH and temperature conditions.
Tuberculosis
The class Ib ribonucleotide reductase from Mycobacterium tuberculosis has two active R2F subunits.
Tuberculosis
The tyrosyl free radical of recombinant ribonucleotide reductase from Mycobacterium tuberculosis is located in a rigid hydrophobic pocket.
Urinary Bladder Neoplasms
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Urinary Bladder Neoplasms
Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
Urinary Bladder Neoplasms
Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer.
Urinary Bladder Neoplasms
RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
Uterine Cervical Neoplasms
(E)-2'-deoxy-2'-(fluoromethylene) cytidine potentiates radioresponse of two human solid tumor xenografts.
Uterine Cervical Neoplasms
Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells.
Uterine Cervical Neoplasms
Gemcitabine and carboplatin demonstrate synergistic cytotoxicity in cervical cancer cells by inhibiting DNA synthesis and increasing cell apoptosis.
Uterine Cervical Neoplasms
Long noncoding RNA LINC00958 regulates cell sensitivity to radiotherapy through RRM2 by binding to microRNA-5095 in cervical cancer.
Uterine Cervical Neoplasms
Molecular Strategies of Deoxynucleotide Triphosphate Supply Inhibition Used in the Treatment of Gynecologic Malignancies.
Uterine Cervical Neoplasms
Radiosensitization of Human Cervical Cancer Cells by Inhibiting Ribonucleotide Reductase: Enhanced Radiation Response at Low-Dose Rates.
Uterine Cervical Neoplasms
Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis.
Vaccinia
Acidic C terminus of vaccinia virus DNA-binding protein interacts with ribonucleotide reductase.
Vaccinia
Allosteric regulation of vaccinia virus ribonucleotide reductase, analyzed by simultaneous monitoring of its four activities.
Vaccinia
Amplification of the ribonucleotide reductase small subunit gene: analysis of novel joints and the mechanism of gene duplication in vaccinia virus.
Vaccinia
Cloning of the vaccinia virus ribonucleotide reductase small subunit gene. Characterization of the gene product expressed in Escherichia coli.
Vaccinia
Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.
Vaccinia
Differential effects of hydroxyurea upon deoxyribonucleoside triphosphate pools, analyzed with vaccinia virus ribonucleotide reductase.
Vaccinia
Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators.
Vaccinia
Gene translocations in poxviruses: the fowlpox virus thymidine kinase gene is flanked by 15 bp direct repeats and occupies the locus which in vaccinia virus is occupied by the ribonucleotide reductase large subunit gene.
Vaccinia
Generation of an attenuated Tiantan vaccinia virus by deletion of the ribonucleotide reductase large subunit.
Vaccinia
Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence in vivo.
Vaccinia
Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: ribonucleotide reductase maturation as a probe of intracellular iron pools.
Vaccinia
Mouse ribonucleotide reductase control: influence of substrate binding upon interactions with allosteric effectors.
Vaccinia
Nucleotide sequence and molecular genetic analysis of the large subunit of ribonucleotide reductase encoded by vaccinia virus.
Vaccinia
Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.
Vaccinia
Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer.
Vaccinia
Purification, crystallization and preliminary diffraction studies of an ectromelia virus glutaredoxin.
Vaccinia
Roles of vaccinia virus ribonucleotide reductase and glutaredoxin in DNA precursor biosynthesis.
Vaccinia
Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs.
Vaccinia
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.
Vaccinia
The sequences of the ribonucleotide reductase genes from African swine fever virus show considerable homology with those of the orthopoxvirus, vaccinia virus.
Vaccinia
Vaccinia virus ribonucleotide reductase expression and isolation of the recombinant large subunit.
Vaccinia
Vaccinia virus ribonucleotide reductase. Correlation between deoxyribonucleotide supply and demand.
Vaccinia
Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis.
Vaccinia
Vaccinia virus-encoded ribonucleotide reductase: sequence conservation of the gene for the small subunit and its amplification in hydroxyurea-resistant mutants.
Vaccinia
Vaccinia virus-induced ribonucleotide reductase can be distinguished from host cell activity.
Vaginal Neoplasms
Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.
Vaginal Neoplasms
Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers.
Virus Diseases
Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro.
Virus Diseases
Partial purification and characterization of the ribonucleotide reductase induced by herpes simplex virus infection of mammalian cells.
Virus Diseases
Partial Purification and Characterization of the Ribonucleotide Reductase Induced by Herpes Simplex Virus Infection of Mammalian Cells.
Virus Diseases
Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.
Virus Diseases
Ribonucleotide reductase: an important enzyme in the replication of herpes simplex virus type 1 and a target for antiviral chemotherapy.
Virus Diseases
The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection.
Virus Diseases
Vaccinia virus ribonucleotide reductase. Correlation between deoxyribonucleotide supply and demand.
Vulvar Neoplasms
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.
Waldenstrom Macroglobulinemia
Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
Wilms Tumor
The 11p15.5 ribonucleotide reductase M1 subunit locus is not imprinted in Wilms' tumour and hepatoblastoma.
Xeroderma Pigmentosum
Altered gene expression in human cells treated with the insecticide diazinon: correlation with decreased DNA excision repair capacity.
Xeroderma Pigmentosum
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Xeroderma Pigmentosum
ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Xeroderma Pigmentosum
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.
Xeroderma Pigmentosum
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
Xeroderma Pigmentosum
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
Yellow Fever
Regulation of the ribonucleotide reductase small subunit (R2) in the yellow fever mosquito, Aedes aegypti.
Yellow Fever
Ribonucleotide reductase subunits from the yellow fever mosquito, Aedes aegypti: cloning and expression.
html completed